Dallas, TX -- Stonegate Capital Partners has updated its coverage on Cingulate Inc. (NASDAQ: CING), emphasizing that the company's fourth quarter 2025 update positions CTx-1301 toward a potential commercial launch for attention deficit hyperactivity disorder (ADHD). The regulatory focus has shifted to manufacturing (CMC) rather than clinical performance, with the New Drug Application (NDA) remaining under FDA review under the 505(b)(2) pathway. The company has made progress in financing, intellectual property, and commercial buildout, which supports the broader investment thesis.
Following a $12 million private investment in public equity (PIPE) completed in February 2026, Cingulate reports a pro forma cash balance of approximately $23 million, which Stonegate estimates provides operational runway into late 2026. Combined with ongoing access to capital through its at-the-market (ATM) and equity line of credit (ELOC) facilities, the company is positioned to fund regulatory and manufacturing activities as it resolves remaining CMC items.
Key takeaways from the update include that FDA feedback has been limited to manufacturing and CMC issues, with no safety or efficacy concerns. This positions the remaining work as addressable process validation rather than a clinical risk. While regulatory timing may shift, approval remains likely, as the delay is driven by manufacturing validation and not fundamental issues with the product profile.
The large ADHD market opportunity is underscored by the potential for CTx-1301. According to the company, capturing a 1% market share implies approximately $250 million in revenue potential, primarily targeting the booster-dose segment. This highlights the significance of the regulatory progress and the commercial buildout efforts.
Stonegate Capital Partners, a capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services, published this update. The full announcement, including downloadable images and bios, is available at Stonegate's website. For more information, contact Stonegate Capital Partners at (214) 987-4121 or visit https://www.stonegateinc.com.
